Waverley Pharma Inc.
WAVE.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -77.09% | -- | -- | -72.90% | -72.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -77.09% | -- | -- | -72.90% | -72.68% |
| Cost of Revenue | -89.31% | -- | -- | -33.55% | -67.44% |
| Gross Profit | -41.85% | -- | -- | -248.35% | -81.28% |
| SG&A Expenses | -71.14% | -50.45% | -40.88% | 17.42% | -42.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.51% | -20.23% | -49.01% | -31.80% | -7.92% |
| Operating Income | 20.02% | -32.22% | 30.40% | 18.42% | -382.30% |
| Income Before Tax | 13.41% | -40.47% | 21.95% | -541.91% | -147.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.41% | -40.47% | 21.95% | -541.91% | -147.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.41% | -40.47% | 21.95% | -541.91% | -147.70% |
| EBIT | 20.02% | -32.22% | 30.40% | 18.42% | -382.30% |
| EBITDA | -11.48% | -51.06% | 40.50% | 21.51% | -320.79% |
| EPS Basic | 13.95% | -42.42% | 21.74% | -550.00% | -152.94% |
| Normalized Basic EPS | 14.81% | -38.10% | 20.69% | -83.33% | -145.45% |
| EPS Diluted | 2.67% | -121.21% | 51.35% | -550.00% | -341.18% |
| Normalized Diluted EPS | 14.81% | -38.10% | 20.69% | -83.33% | -145.45% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |